Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE
- Velinotamig represents a globally licensed, all-indication asset outside Greater China
- Data may materially influence velinotamig’s development strategy and valuation, with full results in Exhibit 99.1
Item 8.01 · Other Events
- Interim Phase 1b/2a data for velinotamig in refractory SLE, with 12 patients treated across three multi-dose cohorts
- Favorable safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS
- Eight of nine evaluable patients achieved at least a four-point SLEDAI-2K reduction after four weeks
- Five of seven patients with baseline proteinuria above 500 mg/24 hours had rapid reductions, including four complete renal responses within 24 weeks
- Early efficacy supports continued development, but limited sample size and interim data leave durability and regulatory potential unproven
Item EX-99.1 · Exhibit EX-99.1
- Interim Phase 1b/2a data support velinotamig’s autoimmune proof of concept, with meaningful disease improvement in 8 of 9 evaluable SLE patients
- Renal signal particularly strong: 4 of 7 patients with baseline proteinuria achieved complete renal responses within 24 weeks
- Favorable early safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS among 12 treated patients
- Serologic and pharmacodynamic effects included reduced anti-dsDNA antibodies, IgG, and CD19-positive B cells, supporting plasma-cell targeting
- Small, early dataset remains nonconfirmatory, but strengthens Cullinan’s broader BCMA strategy and autoimmune cytopenia development plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.